论文部分内容阅读
对72例老年阵发性心房颤动患者随机应用心律平(n=42)和双异丙吡胺(n=30)治疗及预防复发,平均剂量分别为420±198mg/d和412±186mg/d,随访3～24个月,两组即刻复律与近期(6个月内)预防复发疗效相似(总有效率分别为74.5%、69%和70%、53.3%,P值均>0.05),远期(12～24个月)疗效心律平组明显优于双异丙吡胺组(总有效率分别为61.9%和33.3%,P<0.05).心律平组副作用发生率为14.3%,显著低于双异丙吡胺组的43.3%(P<0.01),但均无严重的毒副反应和发生新的心律失常.
A total of 72 elderly patients with paroxysmal atrial fibrillation were randomized to receive ropivacaine (n = 42) and diclofenac (n = 30) and to prevent recurrence with mean doses of 420 ± 198 mg / day and 412 ± 186 mg / day, respectively , Followed up for 3 to 24 months. The immediate cardioversion in both groups was similar to the recent ones (within 6 months) in preventing recurrence (the total effective rates were 74.5%, 69% and 70%, 53.3%, P> 0.05) Long-term (12 ~ 24 months) efficacy of the rhythm group was significantly superior to the dipyridamole group (total effective rate was 61.9% and 33.3%, P <0.05) .The incidence of side effects of rhythm group was 14.3% Lower than 43.3% (P <0.01) in the bisopyriodipine group, but no serious side effects and new arrhythmias occurred.